Products Description
English name：Infliximab
CAS number：170277-31-3
molecular formula
Molecular weight: 0
EINECS No
Related category: mAb 12; control product; chemical reagent
The Mol file: Mol File
structural formula:
Nature of infliximab administration
Storage conditions: Store at-30 C
Form: solid
Color: white to off-white
Use and synthesis method of infliximab
Bioactivity
Infliximab (Avakine) is a chimeric monoclonal IgG 1 antibody that binds specifically to TNF- α. Infliximab Prevent the interaction of TNFChemicalbook- α with TNF- α receptor 1 (TNFR 1) and TNFR 2. Infliximab Can be used in the study of autoimmune, chronic inflammatory diseases and diabetic neuropathy.
Target spot
TNF-α
In vitro study
TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab restores phosphorylation of substrate-2 and AKT by attenuating protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.
In vivo research
A single injection of Infliximab (10 μg/g in 100 μl saline/dose ip) in diabetic TNF-α +/+ ) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 weeks. The increased TNF-α mRNA expression in diabetic dorsal root ganglion is also attenuated by Infliximab.
Security information
Toxic substances data: 170277-31-3 (Hazardous Substances Data)
Hot Tags: infliximab is a chimeric monoclonal igg1 antibody, China infliximab is a chimeric monoclonal igg1 antibody suppliers, 815610-63-0, 380610-27-5, origin pharma packaging, Lecanemab Monoclonal Antibody for Alzheimer s Disease, Alemtuzumab treats leukemia, biosimilars
